ICOTYDE - Concomitant Use with Vaccines in Patients with Plaque Psoriasis

Summary

• The company cannot recommend any practices, procedures, or usage of ICOTYDE that deviate from the approved labeling.
• Please refer to the local labeling for relevant information regarding vaccinations with ICOTYDE.

COMPANY CORE DATA SHEET

Warnings and Precautions

Immunizations

• Prior to initiating therapy with ICOTYDE, consider completion of all age-appropriate immunizations according to current immunization guidelines.¹ 
• No data are available on the response to live or inactive vaccines.¹ 
• Avoid use of live vaccines in patients during treatment with ICOTYDE. Live vaccines may be administered 3 days after discontinuation of ICOTYDE.¹

CLINICAL PROTOCOLS

Bissonnette et al (2025)², Gooderham et al (2025)³, and Stein Gold et al (2025)⁴ reported the exclusion criteria for the ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 phase 3 clinical trials evaluating ICOTYDE in patients with moderate to severe plaque psoriasis.

• Exclusion criteria were assessed during the screening period (weeks -5 to 0) and at week 0 (before first dose of study intervention).^2-4
• Prohibited medications or class of medications included live virus or bacterial vaccination. The restricted duration (through end of study) was 4 weeks, or longer if required per vaccine package insert, prior to the first administration of study intervention.^2-4 

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 22 June 2026.